11Mar 2024
Novo Nordisk’s Wegovy Received FDA Approval for Reducing Cardiovascular Risks in Adults with Obesity

Novo Nordisk’s Wegovy Received FDA Approval for Reducing Cardiovascular Risks in Adults with Obesity

Novo Nordisk's Wegovy receives FDA approval for reducing cardiovascular risks in adults with overweight or obesity and established cardiovascular disease. The approval is based on the SELECT trial, showing a 20% risk reduction in major cardiovascular events compared to placebo. Additional data demonstrate reduced risks of cardiovascular death and overall mortality. Wegovy is now indicated for long-term weight management and cardiovascular risk reduction. Novo Nordisk also seeks label expansion in the EU. Obesity, a chronic disease, necessitates sustained management due to its numerous health complications.

  • #family health

Like

Save

Share